List view / Grid view
30 September 2016 | By Niamh Louise Marriott, Digital Content Producer
6 years after receiving a single treatment with gene therapy, patients with the debilitating genetic disease LPLD had 50% fewer episodes of pancreatitis...
30 September 2016 | By Cherwell Laboratories
Overall demand up by 15% with on-site calibrations showing most significant rise...
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE are recommending it as an option to treat adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy...
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Under the terms of the collaboration, Boehringer Ingelheim receives the right to acquire ViraTherapeutics after conclusion of Phase I clinical development...
28 September 2016 | By European Pharmaceutical Review
European Pharmaceutical Review invites you to participate in this brief survey on Pharmaceutical Water Testing for the chance to win one of 40+ Amazon Gift Cards ranging from €5 to €100!
28 September 2016 | By Syrris
Syrris, a world leader in chemistry product innovation, is launching the Orb Pilot jacketed reactor this fall...
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Approximately 10% of the general population suffer from onychomycosis and a majority of those afflicted go untreated. The prescription market is growing...
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Bristol-Myers' Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression and NKTR-214 is an immuno-stimulatory therapy...
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
For the treatment of pancreatic cancer, EryTech are now looking to develop 'tumour starvation' treatments for acute leukaemia and have enrolled their...
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The primary endpoint of the trial being the percentage of patients who achieved a sustained virologic response 12 weeks after treatment (SVR12)...
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The drug is the first treatment to target hypophosphatasia, a condition affecting the development of bone, and could allow children to lead a normal life...
27 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The expanded use is for Ilaris, a selective, high-affinity, human monoclonal antibody that inhibits Interleukin-1 (IL-1) beta, part of the immune system...
27 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Until now, the time-consuming marketing authorisation process was the only path to being able to market products containing St John’s Wort and Valerian...
27 September 2016 | By Niamh Louise Marriott, Digital Content Producer
In July, Sanofi revealed the development agreement with the Walter Reed Army Institute of Research on the co-development of a Zika vaccine candidate...
27 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Also known as "Butterfly skin" syndrome, epidermolysis bullosa (EB) is a rare genetic skin disease that is caused by the absence of a gene (COL7A1)...
